[SBU should investigate what is an evidence-based and cost-effective use of statins].
Hjemdahl
Paul
P
Karolinska universitetssjukhuset, Solna. Paul.Hjemdahl@ki.se
Allhammar
Anette
A
Heaton
Claire
C
Hulting
Johan
J
Kahan
Thomas
T
Malmström
Rickard
R
Martinsson
Arne
A
Rücker
Franz
F
Schenck-Gustafsson
Karin
K
Schwieler
Jonas
J
Törnerud
Mattias
M
Wettermark
Björn
B
D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control; D003362:Cost-Benefit Analysis; D004363:Drug Utilization / Q000191:economics; D019317:Evidence-Based Medicine; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D019821:Simvastatin / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D013548:Sweden
D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D019821:Simvastatin